What Bronkaid Treats: Main Uses and Benefits

The primary therapeutic use of this combination product is the temporary relief of mild symptoms of intermittent asthma. The product is formulated to address symptoms related to heightened physiological activity in the respiratory tract.

---

Symptom Relief and Application Context

Bronkaid is commonly used to help provide symptomatic relief from the acute physical discomfort of restrictive airway symptoms, including occasional wheezing, temporary shortness of breath, and the sensation of chest tightness. It is also applied in clinical settings where patients experience symptoms related to bronchial congestion and difficulty in clearing thick, tenacious mucus, typically associated with conditions like the common cold or bronchitis. The combination is primarily relevant for episodes involving both airway constriction and secretion impairment, and is used when short-term symptomatic assistance is needed.

The combined symptomatic relief is summarized as: “This medication may assist in easing the overall symptom load by supporting the easing of restrictive airway symptoms and assisting with the management of lower respiratory secretions.”

---

Quick Facts

Property	Description
Quick Fact: Relief for Airway Constriction	Helps ease temporary wheezing and chest tightness.
Quick Fact: Relief for Congestion	Supports mucus thinning for managing a productive cough.
Quick Fact: Context of Use	Relevant for acute, temporary symptomatic respiratory episodes.

Regulatory References

1. DailyMed Label for Bronkaid Max

Who Can and Cannot Use Bronkaid?

Eligibility for Bronkaid use is defined by specific age restrictions, contraindications, and comorbidity-based limitations detailed in official regulatory labeling.

---

Population Eligibility Rules

Category	Official Regulatory Statement
Populations Permitted	Adults and children 12 years of age and over are permitted for use.
Age Restriction	Children under 12 years of age must not use the product.

---

Absolute Contraindications

Use is absolutely prohibited for patients currently taking or having recently taken (within two weeks) a Monoamine Oxidase Inhibitor (MAOI). It is also contraindicated for individuals with a known allergic reaction (hypersensitivity) to Ephedrine Sulfate, Guaifenesin, or any other product ingredients.

---

Conditions Requiring Conditional Use

Individuals with specific chronic conditions are restricted from self-medication and must ask a doctor before use. These conditions include heart disease, high blood pressure, thyroid disease, diabetes, seizures, narrow angle glaucoma, or trouble urinating due to an enlarged prostate gland. Furthermore, patients who have ever been hospitalized for asthma must seek professional consultation.

---

Pregnancy and Lactation Status

Use during pregnancy or while breast-feeding is restricted and requires consultation; individuals must ask a health professional before use.

Interactions with other medicines and products for Bronkaid are predominantly driven by the Ephedrine Sulfate component, focusing on cardiovascular and central nervous system effects documented in regulatory labeling.

Contraindicated and Restricted Combinations

The co-administration of this medicine with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the risk of severe hypertensive crisis. A mandated time separation rule requires that the product must not be administered during or within 14 days following the administration of MAOIs. Ergot Alkaloids are also strictly restricted because of the potential for potent pressor effect augmentation.

Documented Interaction Patterns

The product has official interactions across several categories:

• Pharmacodynamic Augmentation: Other Sympathomimetic Agents, Tricyclic Antidepressants, and Oxytocic Drugs are documented to augment the pressor effect, increasing the risk of cardiovascular events. Cardiac Glycosides increase the possibility of cardiac arrhythmias.
• Antagonism of Effects: Ephedrine is documented to inhibit the effects of certain antihypertensive agents, such as Guanethidine, resulting in the loss of blood pressure control.
• Pharmacokinetic Changes: Substances that alkalinize urine, such as Acetazolamide, are stated to increase the plasma concentration of Ephedrine Sulfate by reducing its renal clearance.
• Substance Interactions: Warnings are documented regarding additive central nervous system (CNS) effects when co-administered with Alcohol and Caffeine-containing products, as well as certain Herbal Products like St. John’s Wort.

Interaction-related considerations also exist for patients with Renal Impairment due to slowed elimination.

Sympathetic Modulation and Airway Relaxation

Ephedrine modulates the Sympathetic Nervous System (SNS) by acting as a mixed-agent: it directly stimulates adrenergic receptors (specifically beta2 and alpha1) and indirectly increases synaptic norepinephrine concentration by promoting its release and inhibiting its reuptake. Activation of beta2 receptors on bronchial smooth muscle cells triggers a cascade that results in muscle relaxation (bronchodilation). Simultaneously, alpha1 receptor stimulation in the respiratory mucosa causes vasoconstriction, modifying mucosal blood flow and reducing the volume of the airway lining, which leads to a net increase in airway diameter.

Secretion Regulation and Systemic Consequences

Guaifenesin affects the physical properties of respiratory secretions. It stimulates vagal afferent receptors in the stomach, activating the gastro-pulmonary reflex. This reflex arc returns to the airways, promoting increased fluid volume and decreased viscosity of secretions, supporting the physical properties necessary for mucociliary transport. Ephedrine's non-selective binding also involves beta1 receptors in the heart and central pathways, leading to generalized cardiovascular stimulation (increased heart rate and blood pressure) and central nervous system arousal.

Administration and Dosing Principles

The established usage protocol for Bronkaid, an oral solid dosage form containing Ephedrine Sulfate, is defined for temporary relief. The administration route is oral, meaning the medicine is swallowed.

Standard Regimen

The standard single dose is one caplet, which contains 25 mg of Ephedrine Sulfate. This oral dose may be taken every four hours as needed for symptomatic management. The daily limit is established such that the total intake must not exceed six caplets in any 24-hour period. This corresponds to a maximum daily dose of 150 mg of Ephedrine Sulfate.

Usage Constraint	Requirement
Route of Administration	Oral
Dosing Frequency	Every four hours, as needed
Maximum Daily Limit	6 caplets in 24 hours
Duration Constraint	Not to be used for more than 7 consecutive days

Administration Contexts

The instructions structure the use of the medicine as a short-term intervention, stating that it should not be used for more than seven consecutive days. The caplet may be taken without regard to meal timing. Furthermore, the product’s use is restricted by age: it is approved for adults and children 12 years of age and over. Use in children under 12 years of age is not recommended within these standardized parameters.

These constraints define the approach to administering the medicine, establishing the limits of dose, frequency, and course duration.

Research Evidence / Overview of Studies for Bronkaid

Evidence for Use in Mild Intermittent Asthma Symptoms

The regulatory evidence for the bronchodilator component, Ephedrine Sulfate, is primarily rooted in historical trials evaluating symptomatic change. This body of research informed the U.S. Food and Drug Administration (FDA) regulatory status for this type of medication within the Over-The-Counter (OTC) Monograph system. Research has examined outcomes related to physical discomfort, specifically focusing on patient-reported outcomes describing perceived discomfort from wheezing and chest tightness. These observed changes were generally short-term, consistent with findings observed in studies of this type of agent.

The certainty surrounding the evidence base for this specific combination product remains low. Since the regulatory basis is historical, there are limited or no modern randomized controlled trials (RCTs) comparing the exact ephedrine/guaifenesin pairing against the prescription standard-of-care treatments currently available for asthma. Consequently, long-term effects are not fully established, and this research provides context but not individual predictions about symptom response.

---

Evidence for Use in Bronchial Congestion and Mucus Thinning

The expectorant component, Guaifenesin, was evaluated in short-term randomized controlled trials as part of research exploring how symptoms change over defined time intervals. Studies examined outcomes linked to inflammatory or irritative states, such as the frequency and severity of coughing, and measured changes in sputum properties.

Findings related to what the expectorant was studied for have been mixed, as some studies report patterns where symptoms evolved in the observed populations, while others showed little difference compared to a placebo. The evidence for Guaifenesin contributes to the broader evidence landscape for expectorants but the certainty of findings from studies exploring acute cough and sputum clearance remains low to moderate overall.

---

Limitations and Research Uncertainty

Several key limitations shape the current understanding of the evidence for this combination product. Comparative evidence is lacking, meaning there are few studies directly comparing the combination product to other current treatments for the conditions it addresses. The evidence quality varies across studies, with a significant portion of the regulatory framework relying on historical data accepted via the OTC Monograph process. Consequently, the certainty remains low regarding the full range of its effects across different patient groups, and the research provides context but not individual predictions.

How to Store and Dispose of Bronkaid?

Bronkaid caplets must be stored under conditions defined by the regulator to maintain product stability and ensure safety.

---

Storage Requirements

Condition	Requirement
Temperature	Controlled room temperature: 20^circC to 25^circC (68^circF to 77^circF), with excursions up to 30^circC (86^circF).
Protection	Must be stored in a dry place.
Child Safety	Must be stored out of reach of children to prevent accidental overdose.

---

Disposal Guidelines

Official disposal instructions recommend utilizing a drug take-back program for unused or expired caplets. If a take-back program is unavailable, the product should be mixed with an unappealing material (such as dirt or used coffee grounds) and sealed in a plastic bag before being discarded in the household trash. Any personal information on the packaging must be removed or concealed prior to disposal.